---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-001183"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T16:48:57.823691+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cassava Sciences Reports 2024 Financial Results and Provides Business Update

## Summary
- Net loss of $24.3 million ($0.53 per share) in 2024 vs $97.2 million in 2023; cash and equivalents $128.6 million with no debt.
- Top-line data for REFOCUS-ALZ, second Phase 3 study of simufilam in Alzheimer's, expected late Q1/early Q2 2025.
- RETHINK-ALZ Phase 3 study did not meet co-primary endpoints in November 2024; all Alzheimer's clinical studies discontinued.
- License agreement with Yale University to explore simufilam for seizures related to tuberous sclerosis complex (TSC).
- G&A expenses rose to $71.8 million in 2024 due to $40 million SEC settlement and higher stock-based compensation.

## SEC filing metadata
- accession: 0001171843-25-001183
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000117184325001183/0001171843-25-001183-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000117184325001183/f8k_030325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-001183
- JSON: https://secwatch.observer/filing/0001171843-25-001183.json
- Plain text: https://secwatch.observer/filing/0001171843-25-001183.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.